MaaT Pharma
Created in 2014
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
12,594Activities
Technologies
Entity types
Location
70 Av. Tony Garnier, 69007 Lyon, France
Lyon
France
Employees
Scale: 51-200
Estimated: 76
SIREN
808370100Engaged corporates
25
8 21Added in Motherbase
4 years, 7 months ago
biotech Value proposition
The leading microbiome company in oncology
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
Microbiome, Microbiota, Microbiology, pharma, GvHD, Leukemia, Dysbiosis, Symbiosis, Biotech, oncology, cancer, gut microbiota, allo-HSCT, and Gut microbiomeOriginal language
The leading microbiome company in oncology
MaaT Pharma has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating blood cancers and graft-versus-host disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has already achieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into larger indications, we have built a powerful discovery and analysis platform to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. Our therapeutics are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spear-head microbiome treatment integration into clinical practice.
Hervé Affagard, CEO & Co-founder
MaaT Pharma - Building a leading microbiome company in oncology
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
https://www.maatpharma.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 | Gouvernement | Other 29 Mar 2024 | | |
 Direction Générale des Entreprises National and local authorities, Government Administration | Direction Générale des Entreprises National and local authorities, Government Administration | Other 29 Mar 2024 | | |
 | Ministère de la Santé | Other 11 Apr 2024 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Not capitalistic Partnership Event 22 Apr 2024 | | |
 INRAE Research, Research Services | INRAE Research, Research Services | Not capitalistic Not partnership Event 2 May 2024 | | |